Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
unlimited free pdf from europmc34933115    free
PDF from PMC    free
html from PMC    free
PDF vom PMID34933115  :  Publisher
PDF vom PMID34933115 :   free
PDF vom PMID34933115

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review Ivermectin s suggested benefits are mainly based on potentially biased results #MMPMID34933115
  • Izcovich A; Peiris S; Ragusa M; Tortosa F; Rada G; Aldighieri S; Reveiz L
  • J Clin Epidemiol 2022[Apr]; 144 (ä): 43-55 PMID34933115show ga
  • OBJECTIVE: The objective of this systematic review is to summarize the effects of ivermectin for the prevention and treatment of patients with COVID-19 and to assess inconsistencies in results from individual studies with focus on risk of bias due to methodological limitations. METHODS: We searched the L.OVE platform through July 6, 2021 and included randomized trials (RCTs) comparing ivermectin to standard or other active treatments. We conducted random-effects pairwise meta-analysis, assessed the certainty of evidence using the GRADE approach and performed sensitivity analysis excluding trials with risk of bias. RESULTS: We included 29 RCTs which enrolled 5592 cases. Overall, the certainty of the evidence was very low to low suggesting that ivermectin may result in important benefits. However, after excluding trials classified as "high risk" or "some concerns" in the risk of bias assessment, most estimates of effect changed substantially: Compared to standard of care, low certainty evidence suggests that ivermectin may not reduce mortality (RD 7 fewer per 1000) nor mechanical ventilation (RD 6 more per 1000), and moderate certainty evidence shows that it probably does not increase symptom resolution or improvement (RD 14 more per 1000) nor viral clearance (RD 12 fewer per 1000). CONCLUSION: Ivermectin may not improve clinically important outcomes in patients with COVID-19 and its effects as a prophylactic intervention in exposed individuals are uncertain. Previous reports concluding important benefits associated with ivermectin are based on potentially biased results reported by studies with substantial methodological limitations. Further research is needed.
  • |*COVID-19/drug therapy[MESH]
  • |*Ivermectin/therapeutic use[MESH]
  • |Bias[MESH]
  • |Humans[MESH]
  • |Respiration, Artificial[MESH]
  • |SARS-CoV-2[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    43 ä.144 2022